YONDELIS® has been studied in patients with unresectable, locally advanced, and metastatic leiomyosarcoma and liposarcoma. Read the hypothetical case studies below for more information about the appropriate use of YONDELIS® as the first choice for second-line or third-line treatment after an anthracycline-containing regimen.
YONDELIS® (trabectedin) Patient Profiles
A 55-year-old, postmenopausal woman with recurrent uterine leiomyosarcoma, treated with surgery followed by doxorubicin/ifosfamide.
Advanced myxoid round cell liposarcoma of the left leg in a 58-year-old male, treated with surgical resection followed by antracycline plus ifosfamide, and radiotherapy.
Dedifferentiated liposarcoma in the left thigh of a 34-year-old woman, treated with resection and radiotherapy, then ifosfamide/epirubicin after metastasizing to the pleural cavity and thorax.
Recurrent uterine leiomyosarcoma in a 55-year-old woman, treated with surgery followed by gemcitabine/taxane after progression, and, following further progression, doxorubicin/ifosfamide.